Dexcom Insider Sold Over $3.24 Million In Company Stock

Kevin R Sayer, CEO And President at Dexcom DXCM, made a large insider sell on September 15, according to a new SEC filing.

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Sayer sold 6,000 shares of Dexcom at a price of $540.28 per share. The total transaction amounted to $3,243,462.

Following the transaction, Sayer still owns 96,705 shares of Dexcom worth $53,902,883.

Dexcom shares are trading down 1.37% at $557.39 at the time of this writing on Friday morning.

The Importance of Insider Transactions

Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision.

In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.

When a company insider makes a new purchase, that is an indication that they expect the stock to rise.

Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.

Transaction Codes To Focus On

Investors prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.

Check Out The Full List Of Dexcom's Insider Trades.